Article
A randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocin
2020-08-25
Abstract excerpt
<h4>Background</h4> The neuropeptide oxytocin is proposed as a promising therapy for social dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical trials report some benefits of chronic treatment it is unclear whether efficacy may be influenced by dose frequency or genotype. <h4>Methods</h4> In a randomized, double blind, placebo-controlled pharmaco-fMRI trial (150 male subjects)...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 6ae8226d-647b-56f7-a995-a1188edbfa2a
- DOI
- 10.1101/2020.08.23.20180489
